TO THE EDITOR
Acute myeloid leukemia (AML), as suggested by clinical data and murine leukemia models, arises through a multistep process involving more than one genetic alteration.
1,2 Transcription factors (TFs) play an important role in this process as they frequently show recurrent, somatically acquired, chromosomal abnormalities (translocations and inversions) and point mutations. 2, 3 Familial cases of AML are best suited to define the initiating steps in leukemogenesis, and studies of familial AML have identified TF RUNX1 (AML1, CBFA2) as the first known familial leukemia susceptibility gene. 4, 5 Core-binding factor CBFb is the cofactor of RUNX1, and both are essential for definitive hematopoiesis and are frequent fusion gene partners in chromosomal translocations in leukemia. 2 Unlike RUNX1 that is also mutated in sporadic leukemia, 2 no somatic point mutations in CBFb were found using SSCP on DNA from 130 sporadic patients with AML or myelodysplastic syndromes. 6 However, in two distinct pedigrees that showed autosomal dominant transmission of AML in three generations, linkage analysis excluded RUNX1 from being causative of the disease, but suggested a second locus for predisposition to leukemia on chromosome 16q22 between D16S451 and D16S515 where CBFb is located. 7, 8 Owing to its close relationship to RUNX1 and its known involvement in leukemia as a translocation fusion partner, CBFb is an outstanding candidate gene for leukemia predisposition in these families. The CBFb gene has six exons and encodes a protein of 182 amino acids or 187 if an alternate splice donor site in exon 5 is used resulting in a different reading frame in exon 6. We performed direct sequencing of all exons and surrounding intronic sequences from affected and unaffected members of both families (for samples, primers and methods, see supplementary information; http://www.mbgproject.org/ SCOTT_LAB/Leukemia.html). In a total of 12 738 base pairs that were sequenced, no sequence variation was found, compatible with homo-or hemizygosity. A germline deletion of RUNX1 resulting in haploinsufficiency has been described in one familial leukemia pedigree. 4 Therefore, we performed SNP, FISH, Northern and RT-PCR analyses to look for loss of heterozygosity and/or haploinsufficiency. A total of 22 reported intragenic SNPs were sequenced from 22 alleles including 10 alleles from controls. Only two SNPs were confirmed, both observed in heterozygosity in unaffected III-5 from family A (see supplementary information, Table 1 ). Owing to the lack of informative SNPs in these families, we could not confirm or exclude a deletion, but FISH failed to detect gross germline deletions or a gene rearrangement in either family (see supplementary information; Figure A) . Northern Blot analyses and semiquantitative RT-PCR using lymphoblastic cell lines of affected and unaffected individuals from both families did not show a reduction in expression between affected and unaffected individuals (see supplementary information; Figure B ).
While we cannot rule out the possibility of a small as yet undetected deletion or other rearrangement of CBFb in these families, a variety of techniques did not reveal any pathogenic germline mutations, and thus CBFb is unlikely to be the '16q22 familial leukemia gene'. 
